Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)

Status:	Completed
Conditions:	Cardiology
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	9/30/2018
Start Date:	July 2009
End Date:	June 2014

This is a prospective randomized controlled trial to compare clinical improvement, cost
effectiveness and patency rates between new and improved Nitinol stents and open bypass
surgery in the superficial femoral artery disease.

Secondary outcomes also include comparing quality of life, re-intervention rate, mortality,
morbidity and time to return to work or regular activities.

Patients with superficial femoral artery lesions will be considered. Patients with TASC II A
lesions will not be randomized but treated with PTA/stenting as standard of care. Patients
with TASC II B and C lesions will be prospectively randomized into either receiving open
bypass or stenting.

Patients with TASC D lesions will be treated with open bypass surgery after angiography.

The investigators will collect pre-procedure, peri-procedural and clinical follow-up data on
all enrolled the patients.

Inclusion Criteria:

Clinical Inclusion:

1. Must be at least 18 years of age.

2. Patient has been informed of the nature of the study, and has provided written
informed consent, approved by the appropriate Institutional Review Board (IRB)/Medical
Ethics Committee (MEC) of the respective clinical site.

3. Symptomatic patient as evidence by IC or CLI.

4. Patient has failed maximized medical treatment and exercise program.

5. Patient has a resting ABI < 0.9 or an abnormal exercise ABI if resting ABI is
normal.Patient with non-compressible arteries (ABI > 1.2) must have a TBI < 0.8.

6. Patient has a de novo or restenotic lesion(s) with > 50% stenosis documented
angiographically.

7. Patient agrees to return for all required clinical contacts following study
enrollment.

8. Patient has no childbearing potential or has a negative pregnancy test within one week
prior to the study procedure.

Anatomical Inclusion:

1. Patient with any SFA lesion

2. At least one tibial vessel runoff with < 50% stenosis

3. Lesion starts start at least 1 cm distal to the deep femoral artery

4. Lesion end at least 3 cm above the knee joint

5. Target vessel reference diameter is > 3 mm & < 6.5 mm

Exclusion Criteria:

Clinical exclusion:

1. Known allergic reaction to anesthesia not able to overcome by medication.

2. Known allergic reaction to contrast not able to overcome by medication.

3. Known history of intolerance to study medicating including ASA, clopidogrel, or
ticlopidine.

4. Bleeding disorder or refuses blood transfusion.

5. Prior stenting or bypass of SFA (prior PTA is not an exclusion criteria)

6. Unstable angina, recent MI within a month

7. Malignancy or other condition limiting life expectancy to < 5 years.

8. Renal insufficiency (serum Cr > 2.0)

9. Patient has any condition that precludes proper angiographic assessment or makes
percutaneous arterial access unsafe (e.g., morbid obesity).

Anatomic Exclusion:

1. Lesion < 1 cm from origin of DFA

2. Lesion < 3 cm from the knee joint

3. Chronic total occlusion of SFA > 20cm.

4. Chronic total occlusion of CFA.

5. Proximal trifurcation occlusions.

We found this trial at

sites

Johns Hopkins Bayview Medical Center

4940 Eastern Ave
Baltimore, Maryland 21224

(410) 550-0100